The Evolving Role of Cytokine-Based Therapy in Patients With Melanoma Progression and/or Drug Resistance

Learn how experts incorporate the newest cytokine-based approaches into optimal management of patients with melanoma with an on-demand Webinar plus an expert commentary and a downloadable slideset.
person default
Elizabeth Buchbinder, MD

ClinicalThought

In this commentary, an expert explains how high-dose IL-2 continues to have a role in the management of resistant or progressive melanoma and discusses evolving ways to incorporate IL-2 therapy into melanoma care.

person default Elizabeth Buchbinder, MD Released: February 15, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Clinigen Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue